Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for ch ...

Are you tired of boring dieting and gruesome workouts? Then, medical weight loss treatment can be a solution for you. But ...

Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of drugs commonly prescribed for type 2 diabetes, improve cardiovascular outcomes such as heart failure (HF), acute myocardial ...